aetherAI vs Tempus Digital Pathology
aetherAI fits hospital labs that run the Philips Ultra Fast Scanner and the Philips PS27QHDCR monitor. Its single FDA record, K233126 from May 2024, covers the aetherSlide viewer for primary diagnosis of FFPE surgical pathology slides on that hardware only. The vendor lists bone marrow and colon polyp modules with Taiwan TFDA approval.
Tempus suits a hospital lab that wants Paige's FDA-authorized prostate tool beside its own viewer, and its page says Prostate Detect must be used with specific scanners and viewers. The line holds two FullFocus viewer 510(k)s, K201005 from July 2020 and K241273 from January 2025, plus Paige Prostate Detect, a De Novo authorization (DEN200080, September 2021) with CE-IVDR marking and a vendor-claimed 20% shorter reading time. aetherAI is the weaker buy for a hospital lab that wants an FDA-authorized AI tool beside its viewer, since the K233126 indication carries no AI claim. Paige Predict and the Breast, Lymph Node, GI and PanCancer Detect tools are labeled research use only.
Pathology · Reviewed November 2, 2026

aetherAI
by aetherAI · founded 2015
FDA-cleared slide viewer for hospital pathology labs. Bone marrow and colon polyp AI modules are TFDA approved in Taiwan.
Tempus Digital Pathology
by Tempus AI
Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.
When to pick each one
aetherAI
- Cleared viewer for primary diagnosis, K233126
- Cleared with Philips scanner and monitor
- Bone marrow and polyp modules approved by TFDA
Tempus Digital Pathology
- Paige FullFocus viewer 510(k)s plus Prostate Detect De Novo
- Prostate Detect also carries CE-IVDR
- Vendor claims 20% shorter reading time
Score
Each row shows points earned of points available under the published rubric.
aetherAI
51of 100
Tempus Digital Pathology
38of 100
| Dimension | aetherAI | Tempus Digital Pathology | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 14.7 / 21 | 0 / 21 | +14.7 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 3 / 12 | 12 / 12 | -9 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
aetherAI
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Tempus Digital Pathology
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price on the Tempus pages. |
Evidence
aetherAI
FDA decisions
K233126 (opens in new tab)510(k)2024-05-30
aetherSlide
Peer-reviewed
2 PubMed records name aetherAI.
Tempus Digital Pathology
FDA decisions
K241273 (opens in new tab)510(k)2025-01-09
Paige FullFocus
DEN200080 (opens in new tab)De Novo2021-09-21
Paige Prostate Detect
K201005 (opens in new tab)510(k)2020-07-15
Paige FullFocus
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | aetherAI | Tempus Digital Pathology |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2015 | n/a |
| HQ | TW | US |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.
